1887

Journal of Medical Microbiology logo

Volume 71, Issue 8

Identification and antimicrobial susceptibility of referred isolates in Victoria, Australia 2009–2019 Open Access

Abstract

Nocardia is an opportunistic pathogen that can cause significant morbidity and mortality, particularly in the immunocompromised host. Antimicrobial susceptibility profiles vary across spp. and vary within Australia as well as worldwide. Knowledge of local susceptibility patterns is important in informing appropriate empiric antimicrobial therapy.

This is the largest study to date in Australia that correlates antimicrobial susceptibility profiles with molecular identification of species. It is the first study that examines isolates from multiple institutions across the state of Victoria, Australia.

To investigate the species distribution and antibiotic susceptibility of spp. isolates referred to the Mycobacterial Reference Laboratory (MRL) in Victoria, Australia from 2009 to 2019.

We conducted a retrospective review of spp. isolates which were identified using molecular sequencing. Antimicrobial susceptibility testing was performed using standardized broth microdilution method with Sensititre RAPMYCO1 plates. Species distribution and antibiotic susceptibility profiles were analysed.

In total, 414 isolates were identified to 27 species levels, the majority originating from the respiratory tract (=336, 81.2 %). (=147, 35.5 %) was the most frequently isolated, followed by (=75, 18.1 %). Species distribution varied by isolate source, with and found more commonly from sterile sites. Linezolid and amikacin had the highest proportion of susceptible isolates (100 and 99% respectively), while low susceptibility rates were detected for ceftriaxone (59 %) and imipenem (41 %). Susceptibility to trimethoprim sulfamethoxazole varied by species (0–100 %).

This is the largest study to date in Australia of species distribution and antimicrobial susceptibility patterns. and were more likely to be isolated from sterile sites, while and were more likely to be isolated from skin and soft tissue. First line therapeutic antimicrobial recommendations by local guidelines were not necessarily reflective of the susceptibility of isolates in this study, with high susceptibility detected for linezolid and amikacin, but poor susceptibility demonstrated for ceftriaxone and imipenem. Profiles for trimethoprim-sulfamethoxazole varied across different species, warranting ongoing susceptibility testing for targeted clinical use.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antimicrobial susceptibility , Australia , epidemiology , immunocompromised host , Nocardia and nocardiosis
© 2022 Crown Copyright
  • This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001581
2022-08-17
2024-05-03
Loading full text...

Full text loading...

/deliver/fulltext/jmm/71/8/jmm001581.html?itemId=/content/journal/jmm/10.1099/jmm.0.001581&mimeType=html&fmt=ahah

References

  1. Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 2006; 19:259–282 [View Article] [PubMed]
     [Google Scholar]
  2. Lerner PI. Nocardiosis. Clin Infect Dis 1996; 22:891–903 [View Article] [PubMed]
     [Google Scholar]
  3. Beaman BL, Beaman L. Nocardia species: host-parasite relationships. Clin Microbiol Rev 1994; 7:213–264 [View Article] [PubMed]
     [Google Scholar]
  4. Hamdi AM, Fida M, Deml SM, Abu Saleh OM, Wengenack NL. Retrospective analysis of antimicrobial susceptibility profiles of Nocardia species from a Tertiary Hospital and Reference Laboratory, 2011 to 2017. Antimicrob Agents Chemother 2020; 64:e01868-19 [View Article] [PubMed]
     [Google Scholar]
  5. Valdezate S, Garrido N, Carrasco G, Medina-Pascual MJ, Villalón P et al. Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain. J Antimicrob Chemother 2017; 72:754–761 [View Article] [PubMed]
     [Google Scholar]
  6. Coussement J, Lebeaux D, van Delden C, Guillot H, Freund R et al. Nocardia infection in solid organ transplant recipients: a multicenter European case-control study. Clin Infect Dis 2016; 63:338–345 [View Article] [PubMed]
     [Google Scholar]
  7. Margalit I, Lebeaux D, Tishler O, Goldberg E, Bishara J et al. How do I manage nocardiosis?. Clin Microbiol Infect 2021; 27:550–558 [View Article] [PubMed]
     [Google Scholar]
  8. Tan YE, Chen SC-A, Halliday CL. Antimicrobial susceptibility profiles and species distribution of medically relevant Nocardia species: results from a large Tertiary Laboratory in Australia. J Glob Antimicrob Resist 2020; 20:110–117 [View Article] [PubMed]
     [Google Scholar]
  9. Lebeaux D, Bergeron E, Berthet J, Djadi-Prat J, Mouniée D et al. Antibiotic susceptibility testing and species identification of Nocardia isolates: a retrospective analysis of data from a French expert laboratory, 2010-2015. Clin Microbiol Infect 2019; 25:489–495 [View Article] [PubMed]
     [Google Scholar]
  10. McGuinness SL, Whiting SE, Baird R, Currie BJ, Ralph AP et al. Nocardiosis in the tropical Northern Territory of Australia, 1997-2014. Open Forum Infect Dis 2016; 3:fw208 [View Article] [PubMed]
     [Google Scholar]
  11. Paige EK, Spelman D. Nocardiosis: 7-year experience at an Australian tertiary hospital. Intern Med J 2019; 49:373–379 [View Article] [PubMed]
     [Google Scholar]
  12. Jackson K, Sievers A, Ross BC, Dwyer B. Isolation of a fastidious Mycobacterium species from two AIDS patients. J Clin Microbiol 1992; 30:2934–2937 [View Article] [PubMed]
     [Google Scholar]
  13. CLSI Susceptibility Testing of Mycobacteria, Nocardia spp., and other aerobic actinomycetes. In CLSI Document M24, 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2018
     [Google Scholar]
  14. Schlaberg R, Fisher MA, Hanson KE. Susceptibility profiles of Nocardia isolates based on current taxonomy. Antimicrob Agents Chemother 2014; 58:795–800 [View Article] [PubMed]
     [Google Scholar]
  15. Huang L, Chen X, Xu H, Sun L, Li C et al. Clinical features, identification, antimicrobial resistance patterns of Nocardia species in China: 2009-2017. Diagn Microbiol Infect Dis 2019; 94:165–172 [View Article] [PubMed]
     [Google Scholar]
  16. Uhde KB, Pathak S, McCullum I Jr, Jannat-Khah DP, Shadomy SV et al. Antimicrobial-resistant nocardia isolates, United States, 1995-2004. Clin Infect Dis 2010; 51:1445–1448 [View Article] [PubMed]
     [Google Scholar]
  17. Lowman W, Aithma N. Antimicrobial susceptibility testing and profiling of Nocardia species and other aerobic actinomycetes from South Africa: comparative evaluation of broth microdilution versus the Etest. J Clin Microbiol 2010; 48:4534–4540 [View Article] [PubMed]
     [Google Scholar]
  18. Wauters G, Avesani V, Charlier J, Janssens M, Vaneechoutte M et al. Distribution of nocardia species in clinical samples and their routine rapid identification in the laboratory. J Clin Microbiol 2005; 43:2624–2628 [View Article] [PubMed]
     [Google Scholar]
  19. Antibiotic Expert Group Therapeutic Guidelines: Antibiotic, Version 16 ed. Melbourne: Therapeutic Guidelines Limited; 2019
     [Google Scholar]
  20. Ambaye A, Kohner PC, Wollan PC, Roberts KL, Roberts GD et al. Comparison of agar dilution, broth microdilution, disk diffusion, E-test, and BACTEC radiometric methods for antimicrobial susceptibility testing of clinical isolates of the Nocardia asteroides complex. J Clin Microbiol 1997; 35:847–852 [View Article] [PubMed]
     [Google Scholar]
  21. Conville PS, Brown-Elliott BA, Wallace RJ Jr, Witebsky FG, Koziol D et al. Multisite reproducibility of the broth microdilution method for susceptibility testing of Nocardia species. J Clin Microbiol 2012; 50:1270–1280 [View Article] [PubMed]
     [Google Scholar]
  22. Brown-Elliott BA, Biehle J, Conville PS, Cohen S, Saubolle M et al. Sulfonamide resistance in isolates of Nocardia spp. from a US multicenter survey. J Clin Microbiol 2012; 50:670–672 [View Article] [PubMed]
     [Google Scholar]
  23. Valdezate S, Martínez-Beltrán J, de Rafael L, Baquero F, Cantón R. Beta-lactam stability in frozen microdilution PASCO MIC panels using strains with known resistance mechanisms as biosensors. Diagn Microbiol Infect Dis 1996; 26:53–61 [View Article] [PubMed]
     [Google Scholar]
  24. Steingrube VA, Wallace RJ Jr, Brown BA, Zhang Y, Steele LC et al. Partial characterization of Nocardia farcinica beta-lactamases. Antimicrob Agents Chemother 1993; 37:1850–1855 [View Article] [PubMed]
     [Google Scholar]
  25. Wallace RJ, Nash DR, Johnson WK, Steele LC, Steingrube VA. Beta-lactam resistance in Nocardia brasiliensis is mediated by beta-lactamase and reversed in the presence of clavulanic acid. J Infect Dis 1987; 156:959–966 [View Article] [PubMed]
     [Google Scholar]
  26. Wallace RJ, Vance P, Weissfeld A, Martin RR. Beta-lactamase production and resistance to beta-lactam antibiotics in Nocardia. Antimicrob Agents Chemother 1978; 14:704–709 [View Article] [PubMed]
     [Google Scholar]
  27. Antibiotic Expert Group Therapeutic Guidelines: Antibiotic, Version 15 ed. Melbourne: Therapeutic Guidelines Limited; 2014
     [Google Scholar]
  28. Spelman D. Treatment of Nocardiosis. UpToDate Waltham, WA (Accessed on October 12, 2021): 2021
     [Google Scholar]
  29. Ercibengoa M, Càmara J, Tubau F, García-Somoza D, Galar A et al. A multicentre analysis of Nocardia pneumonia in Spain: 2010-2016. Int J Infect Dis 2020; 90:161–166 [View Article] [PubMed]
     [Google Scholar]
  30. Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW et al. In vitro activities of linezolid against multiple Nocardia species. Antimicrob Agents Chemother 2001; 45:1295–1297 [View Article] [PubMed]
     [Google Scholar]
  31. De La Cruz O, Minces LR, Silveira FP. Experience with linezolid for the treatment of nocardiosis in organ transplant recipients. J Infect 2015; 70:44–51 [View Article] [PubMed]
     [Google Scholar]
  32. Moylett EH, Pacheco SE, Brown-Elliott BA, Perry TR, Buescher ES et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis 2003; 36:313–318 [View Article]
     [Google Scholar]
  33. Davidson N, Grigg MJ, Mcguinness SL, Baird RJ, Anstey NM. Safety and outcomes of linezolid use for nocardiosis. Open Forum Infect Dis 2020; 7:faa090 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001581
Loading
Identification and antimicrobial susceptibility of referred Nocardia isolates in Victoria, Australia 2009–2019
J. Med. Microbiol. 71, 001581 (2022); https://doi.org/10.1099/jmm.0.001581
/content/journal/jmm/10.1099/jmm.0.001581
/content/journal/jmm/10.1099/jmm.0.001581
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error